Prevention of High Altitude Pulmonary Edema
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00274430|
Recruitment Status : Completed
First Posted : January 10, 2006
Last Update Posted : December 4, 2006
A double-blind placebo controlled study
- To compare the effect of tadalafil and dexamethasone versus placebo on Ppa and pulmonary edema formation in subjects susceptible to HAPE.
- To investigate the effect of dexamethasone on alveolar fluid clearance, as assessed by measurement of the nasal potential difference, and prevention of HAPE.
- To investigate the effect of the tadalafil and dexamethasone versus placebo on the dynamic CBF autoregulation properties and on the development of AMS in HAPE susceptible subjects.
|Condition or disease||Intervention/treatment||Phase|
|High Altitude Pulmonary Edema||Drug: dexamethasone 8 mg bid Drug: tadalafil 10mg bid||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized Controlled Trial of the Effects of Tadalafil and Dexamethasone Versus Placebo on Pulmonary Edema Formation and Cerebral Blood Flow Autoregulation in High Altitude Newcomers With a Previous History of High Altitude Pulmonary Edema|
|Study Start Date :||July 2003|
|Estimated Study Completion Date :||September 2003|
- prevention of high altitude pulmonary edema
- incidence of acute mountain sickness
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00274430
|Principal Investigator:||Marco Maggiorini, MD||University of Zurich|